Overview
Title
Product Cancellation Order for Certain Pesticide Registrations and Amendments To Terminate Uses; Amendment
Agencies
ELI5 AI
The EPA is letting a specific bug-fighting chemical, called triadimefon, stay on shelves a bit longer than planned because shipment delays happened. They checked and found no big dangers, so it's okay to use up what's left until then.
Summary AI
The Environmental Protection Agency (EPA) has issued a notice regarding the amendment of a previous cancellation order for two pesticide registrations, specifically for triadimefon. Initially, the cancellation was announced on March 19, 2019, but due to delays in shipments caused by quarantine measures, the effective date of cancellation has been extended to February 28, 2020. This extension allows the sale and use of existing stocks for an additional year, as no significant risks have been identified. This change was requested by Bayer and accepted by the EPA, ensuring that these products can remain available for a limited time longer without posing significant risks.
Abstract
EPA issued a notice in the Federal Register of March 19, 2019, concerning the cancellations voluntarily requested by the registrants and accepted by the Agency but have not yet become effective. This notice is being issued to amend the cancellation order, as requested by the registrant, by amending the effective date of the cancellation and the existing stocks provision for the two triadimefon registrations (264-736 and 264-740).
Keywords AI
Sources
AnalysisAI
Summary of the Document
The document from the Environmental Protection Agency (EPA) details a notice concerning the amendment of a cancellation order for two specific pesticide registrations related to the chemical triadimefon. Originally, the effective date for this cancellation was announced in the Federal Register on March 19, 2019, with a later published correction. However, due to unexpected delays in shipment attributed to quarantine measures, the EPA has decided to extend the effective date until February 28, 2020. This extension was requested by Bayer, the registrant, to allow for managing existing stocks without posing significant risks, as the risks had not been fully assessed at the time of the amendment.
Significant Issues and Concerns
One primary issue is the use of technical terms such as "triadimefon technical registrations," "existing stocks provision," and "risk assessments," which may not be easily understood by the general public. This could lead to confusion or misinterpretation of the document's content and implications. Furthermore, there is no clarification on what "quarantine measures" resulted in the shipment delay and why these specifically impacted the timeline.
The decision assumes no risk of concern despite acknowledgment that risk assessments have not been completed. This may raise questions about whether due diligence has been fully exercised in determining any potential environmental or health impacts. Additionally, the document omits detailed reasons behind the voluntary cancellation request from the registrants, which might be crucial information for understanding the broader context and implications.
Impact on the Public
For the general public, the extension of the cancellation effective date means that the use and distribution of these pesticide stocks can continue temporarily. While the EPA assures that there are no identified significant risks, the public may be concerned about the lack of completed risk assessments. Understanding the exact reasons for the initial voluntary cancellation request would also be beneficial to address any public fears related to health and environmental safety.
Impact on Specific Stakeholders
Stakeholders such as environmental and human health advocates may view the extension with skepticism due to the pending risk assessments. They might advocate for more transparency and comprehensive evaluations before such extensions are granted. On the other hand, stakeholders within the agricultural and chemical industries, including Bayer, are likely to benefit from this decision, as it allows additional time to manage inventory and adapt to regulatory changes without immediate pressure.
In conclusion, while the document seeks to balance industry needs with safety considerations, the lack of complete risk data and specific explanations may raise questions about the thoroughness of the amendment process. The EPA and stakeholders need to ensure open communication and transparency to address public concerns adequately.
Issues
• The document uses technical language which may not be easily understood by the general public, such as 'triadimefon technical registrations', 'existing stocks provision', and 'risk assessments'.
• The document mentions a delay in the final shipments of triadimefon due to quarantine measures, but it does not explicitly clarify what those measures are or why they led to such a delay.
• The amendment extends the cancellation effective date for the two triadimefon registrations without specifying any potential environmental or health impacts, assuming no risks of concern without definitive risk assessments. This could be seen as a lack of thorough evaluation.
• The document does not provide detailed information regarding the reasons for the original voluntary cancellation request by the registrants, which might be important for public understanding of the issue.
• The document mentions the involvement of Bayer in the delay of shipments but does not detail any oversight or accountability measures regarding the delay.